Drugs / Boswellic acids
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01450124 | Sep 2011 → Dec 2014 | relapsing-remitting multiple sclerosis | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boswellic acids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01450124 ↗ |
| Route | Oral | “Boswellic acids (BAs), the main biologically active compound of frankincense, are orally available” NCT01450124 ↗ |